#AAN2018 – Early Data Supports Golodirsen in DMD Patients Amenable to Exon 53 Skipping
News
A potential next-generation therapy, golodirsen (SRP-4053) facilitates and increases dystrophin production in Duchenne muscular dystrophy (DMD) patients, an interim analysis of a Phase 1/2 trial being presented at the 2018 American Academy ... Read more